ClinicalTrials.gg
RecruitingNCT07826871THYMEUpdated Nov 3, 2026

Targeting HealthY Eating to Maintain Energy While Living With Cancer

A Phase 2 interventional study of Nutrition counseling and Time-restricted eating in Fatigue in Cancer Survivors, sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of Maryland, Baltimore · Phase 2, Interventional, and Supportive care

Updated Nov 3, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓
Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

Treatments for advanced and metastatic cancer can cause fatigue and accelerate the progression to frailty. There are few effective mitigation strategies for fatigue or frailty in chronic cancer in part because the underlying etiology and pathophysiology are not well understood. However, disruption of circadian rhythms is a mechanism that possibly underlies fatigue and other components of frailty. Time-restricted eating is a daily eating pattern that entails consuming food within a defined, consistent window (e.g., 10 hours) every day. When the eating window aligns with the daylight hours, it entrains circadian processes and modulates physiological regulation of whole-body metabolism. Stronger physiological regulation means that the body will better be able to respond to physiological perturbations such as standing up from lying down, walking vs. sitting still, and eating food, as well as sleep more efficiently and have more perceived energy during the day. It is also predicted that patients will be less vulnerable to the aging process. It is hypothesized that time-restricted eating can alleviate fatigue and slow the progression to frailty in older adults with cancer as a chronic condition via regulating circadian rhythms and improving physiological responsiveness. This project is a 12-week, two-arm, phase II randomized controlled trial comparing the effects of time-restricted eating (10 h daytime feeding/14 h fasting at night) vs. a nutrition counseling control intervention (no time component) on fatigue; 6- and 12-month follow-up time points are also planned. A total of 132 patients with prostate cancer or metastatic breast cancer will be recruited; eligible participants will be 55 years or older, consume food within a window that is >12 h at baseline, and not be employed in night-shift work. They will be randomized 1:1, intervention: control. At baseline, 12 weeks (post-intervention), and 12 months, we will assess patient-reported fatigue (Aim 1); frailty via Fried's frailty criteria (Aim 2); and measures of circadian rhythms (i.e., rest-activity rhythm, urinary hormones) and physiological responsiveness (i.e., lying vs. standing blood pressure, sitting vs. walking heart rate, glucose tolerance, phosphocreatine recovery) (Aim 3, mechanistic aim). The time-restricted eating intervention is scalable and inexpensive, lending itself to accessibility for the vast majority of people living with cancer as a chronic condition. Data generated herein will be used to inform a larger, phase III multisite clinical trial testing the effects of time-restricted eating on fatigue and frailty among older adults living with cancer and further optimize interventions that entrain circadian rhythms and improve energy production.

02

Conditions studied

  • Fatigue in Cancer Survivors

Keywords

  • intermittent fasting
  • survivorship
  • frailty
  • nutrition
03

In context

Intermittent Fasting

333 studies on the registry are indexed under Intermittent Fasting; 99 are open to participants now.

This study's planned enrollment of 132 is above the median of 50 across 320 interventional studies indexed under Intermittent Fasting.

Browse Intermittent Fasting studies →

Lead sponsor

University of Maryland, Baltimore is the lead sponsor of 700 studies on the registry; 132 are open to participants now.

Of its 92 completed or terminated interventional studies of FDA-regulated products, 66 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of prostate cancer or breast cancer
  • Have current use or a history of hormone therapy (e.g., androgen deprivation therapy, aromatase inhibitors)
  • Have a of ≥1 year
  • Be 55 years of age or older
  • Typically consume food within a window that is greater than 12 hours
  • Be able to communicate in English
  • Have a (BMI) ≥18.5 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Be employed in overnight shift work more than 1 day/week on average
  • Be on enteral or parenteral nutrition
  • Have any to the proposed intervention as identified by their medical provider (e.g., type 1 diabetes, pregnancy, recent history of an eating disorder, recent bariatric surgery, insulin dependency)
  • Have had time zone travel ≥2 time zones away within the last 4 weeks, or have time zone travel (≥2 time zones away) planned for more than 2 days in the next 14 weeks.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Time-restricted eating

    Behavioral: Nutrition counseling · Behavioral: Time-restricted eating

  • Active comparator
    Time-unrestricted eating

    Behavioral: Nutrition counseling

Interventions

  • BehavioralNutrition counseling

    Participants will meet with a nutritionist to discuss their dietary habits and how they compare to the American Cancer Society nutrition guidelines.

  • BehavioralTime-restricted eating

    Participants will be asked to eat all their food in a self-selected 10-hour eating window every day.

06

What researchers measure

Primary outcomes

  1. Fatigue, measured by the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)

    The Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) is a 30-item self-report questionnaire that assesses five dimensions of fatigue: General, Physical, Emotional, Mental, and Vigor. Responses are rated on a 5-point scale based on symptoms experienced during the previous week. The total fatigue score is calculated by summing the General, Physical, Emotional, and Mental Fatigue subscale scores and subtracting the Vigor subscale score. Total scores range from -24 to 96, with higher scores indicating greater fatigue.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Recruiting
changed Nov 3, 2026
Sites
University of Maryland, Baltimore is now Recruiting
Nov 3, 2026
Start date
Oct 2026→Nov 2026
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Not yet recruiting→Recruiting
    University of Maryland, Baltimore is now Recruiting
    Start date Oct 2026→Nov 2026
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07826871
Responsible party
Sponsor
First posted
Sep 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Sep 2031 (estimated)
Completion
Sep 2033 (estimated)
Last update
Nov 3, 2026

Study contacts

Amber Kleckner, PhD
Contact
amber.kleckner@umaryland.edu
4107065961

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion